EUVIMEDEUVIMED entdecken
Open Access

A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening

Yixuan Shang, Dongyu Xu, Lingyu Sun, Yuanjin Zhao iD, Lingyun Sun

Research · 2024-01 · 7

DOI: 10.34133/research.0471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research, online erschienen am 12.09.2024. Verfasst von Yixuan Shang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Ch…. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Key Research and Development Program of China, Key Program of the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac fibrosis has emerged as the primary cause of morbidity, disability, and even mortality in numerous nations. In light of the advancements in precision medicine strategies, substantial attention has been directed toward the development of a practical and precise drug screening platform customized for individual patients. In this study, we introduce a biomimetic cardiac fibrosis-on-a-chip incorporating structural color hydrogels (SCHs) to enable optical high-throughput drug screening. By cocultivating a substantial proportion of cardiac fibroblasts (CFBs) with cardiomyocytes on the SCH, this biomimetic fibrotic microtissue successfully replicates the structural components and biomechanical properties associated with cardiac fibrosis. More importantly, the structural color shift observed in the SCH can be indicative of cardiac contraction and relaxation, making it a valuable tool for evaluating fibrosis progression. By incorporating such fibrotic microtissue into a microfluidic gradient chip, we develop a biomimetic optical cardiac fibrosis-on-a-chip platform that accurately and efficiently screens potential anti-fibrotic drugs. These characteristics suggest that this microphysiological platform possesses the capability to establish a preclinical framework for screening cardiac drugs, and may even contribute to the advancement of precision medicine.

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
  • State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
  • Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.

ORCID-Profile: Yuanjin Zhao

Förderung

  • National Key Research and Development Program of China
  • Key Program of the National Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Clinical Trials from Nanjing Drum Tower Hospital

Zitieren

APA

Shang, Y., Xu, D., Sun, L., Zhao, Y., & Sun, L. (2024). A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening. Research, 7. https://doi.org/10.34133/research.0471

Vancouver

Shang Y, Xu D, Sun L, Zhao Y, Sun L. A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening. Research. 2024;7. doi:10.34133/research.0471

BibTeX
@article{Shang2024,
  author = {Shang, Yixuan and Xu, Dongyu and Sun, Lingyu and Zhao, Yuanjin and Sun, Lingyun},
  title = {A Biomimetic Optical Cardiac Fibrosis-on-a-Chip for High-Throughput Anti-Fibrotic Drug Screening},
  journal = {Research},
  year = {2024},
  volume = {7},
  doi = {10.34133/research.0471}
}
Kostenlos starten →